Bank of New York Mellon’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Bank of New York Mellon’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,200	Closed	-$9.73K	–	4486
2023 Q1	$9.73K	Hold	1,200	–	–	﹤0.01%	4361
2022 Q4	$14.2K	Hold	1,200	–	–	﹤0.01%	4389
2022 Q3	$17K	Hold	1,200	–	–	﹤0.01%	4469
2022 Q2	$42K	Hold	1,200	–	–	﹤0.01%	4384
2022 Q1	$48K	Hold	1,200	–	–	﹤0.01%	4530
2021 Q4	$51K	Hold	1,200	–	–	﹤0.01%	4500
2021 Q3	$81K	Hold	1,200	–	–	﹤0.01%	4371
2021 Q2	$92K	Buy	+1,200	New	+$73.1K	﹤0.01%	4237
2019 Q4	–	Sell	-381	Closed	-$19K	–	4246
2019 Q3	$19K	Hold	381	–	–	﹤0.01%	4185
2019 Q2	$35K	Hold	381	–	–	﹤0.01%	4150
2019 Q1	$56K	Sell	381 -11	-3%	-$2.13K	﹤0.01%	4081
2018 Q4	$62K	Hold	392	–	–	﹤0.01%	4035
2018 Q3	$96K	Hold	392	–	–	﹤0.01%	4046
2018 Q2	$88K	Sell	392 -71	-15%	-$19K	﹤0.01%	4018
2018 Q1	$113K	Buy	463 +60	+15%	+$15.7K	﹤0.01%	4042
2017 Q4	$124K	Buy	403 +11	+3%	+$3.62K	﹤0.01%	4043
2017 Q3	$143K	Buy	392 +222	+131%	+$78.8K	﹤0.01%	3936
2017 Q2	$62K	Buy	+170	New	+$50.9K	﹤0.01%	4106
2016 Q4	–	Sell	-144	Closed	-$34K	–	4321
2016 Q3	$34K	Sell	144 -25	-15%	-$5.2K	﹤0.01%	4179
2016 Q2	$33K	Sell	169 -20	-11%	-$9.22K	﹤0.01%	4235
2016 Q1	$81K	Hold	189	–	–	﹤0.01%	4005
2015 Q4	$72K	Hold	189	–	–	﹤0.01%	4123
2015 Q3	$51K	Hold	189	–	–	﹤0.01%	4238
2015 Q2	$56K	Buy	189 +19	+11%	+$5.74K	﹤0.01%	4152
2015 Q1	$47K	Buy	+170	New	+$73.4K	﹤0.01%	4144

Other funds holding DMK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Bank of New York Mellon's DMK Position: Q2 2023 in Review

Bank of New York Mellon sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 1,200 shares — an estimated $9.73K sold.

Bank of New York Mellon first reported a position in DMK in Q1 2015 and held it in 25 quarters. The position peaked at $143K in Q3 2017. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Bank of New York Mellon reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 1,200 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $9.73K.
Bank of New York Mellon first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2015 and held it in 25 quarters.
Bank of New York Mellon's DMK Pharmaceuticals Corporation Common Stock position peaked at $143K in Q3 2017.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.